All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
VivoCAR™ Anti-CA9 (AB-MN-21.7.1) h(CD28-41BB-CD3z) CAR saRNA employs a self-amplifying RNA backbone to express the AB-MN-21.7.1 clone. For in vivo applications, this clone is prized for its specific recognition of CA9, minimizing the risk of on-target off-tumor effects. The biological magnification effect of the saRNA platform leads to robust CAR expression through intracellular replication, facilitating efficient in situ T-cell modification and sustained anti-tumor activity against CA9-positive malignancies while maintaining a favorable safety profile at lower systemic doses.
There are currently no customer reviews or questions for VivoCAR™ Anti-CA9 (AB-MN-21.7.1) h(CD28-41BB-CD3z) CAR saRNA (XS-0326-XU34). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION